HDAC9 – rs2023938 is a single-nucleotide polymorphism located within or near the HDAC9 gene. HDAC9 belongs to the class IIa histone deacetylase family, a group of epigenetic enzymes that remove acetyl groups from histones and other proteins to modify chromatin accessibility and transcriptional programs. HDAC9 has been studied for its role in regulating gene expression in vascular cells, immune cells, and muscle. Genome-wide association and candidate-gene studies have identified variants at the HDAC9 locus as linked to differences in vascular-related traits and biomarker patterns, making rs2023938 a point of interest when integrating genetic and clinical biomarker data.

Because rs2023938 is a genetic variant, terminology like “higher” or “lower” typically refers to allele-associated differences in HDAC9 expression or function rather than a circulating concentration. Some alleles at this locus have been associated with increased HDAC9 expression or activity in research cohorts, which in turn can correlate with biomarker patterns such as altered inflammatory signaling, endothelial function markers, or lipid-related profiles in certain populations. Other alleles are associated with comparatively lower HDAC9 expression or activity and may track with the opposite biomarker patterns. These associations are modest and variable by population; interpretation is most reliable when integrated with Cardio Zoomer’s biochemical markers, clinical context, and other genetic findings.

Cardio Zoomer includes HDAC9 – rs2023938 to provide inherited insight into epigenetic control of vascular biology. This marker helps connect a person’s genetic tendency for chromatin-mediated regulation with measured inflammation, endothelial, and lipid patterns, improving interpretation of composite cardiovascular risk signals.